The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
BagshaweK.D.Treatment of trophoblastic tumors. Ann Acad Med Singapore.1976; 5: 273–279.
WeedJ.C.Jr, BarnardD.E., CurrieJ.L., ClaytonL.A., HammondC.B.Chemotherapy with the modified Bagshawe protocol for poor prognosis metastatic trophoblastic disease. Obstet Gynecol.1982; 59: 377–380.
4.
CurryS.L., BlessingJ.A., DiSaiaP.J., SoperJ.T., TwiggsL.B.A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, melphalan, hydroxyurea, and vincristine in “poor prognosis” metastatic gestational trophoblastic disease: a Gynecologic Oncology Group Study. Obstet Gynecol.1989; 73: 357–362.
5.
SurwitE.A., SuciuT.N., SchmidtH.J., HammondC.B.A new combination chemotherapy for resistant tropholastic disease. Gynecol Oncol.1979; 8: 110–118.
6.
SurwitE.A., HammondC.B.Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol.1980; 55: 565–570.
7.
TrisselL.A., ZhangY., CohenM.R.The stability of diluted vincristine sulfate used as a deterrent to inadvertent intrathecal injection. Hosp Pharm.2001; 36: 740–745.
8.
HeskethP.J., KrisM.G., GrunbergS.M.. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15: 103–109.
9.
National Comprehensive Cancer Network. NCCN antiemesis practice guidelines. Available at: http://www.nccn.org/. Accessed December 24, 2005.
10.
GrallaR.G., OsobaD., KrisM.G.. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol.1999; 17: 2971–2994.
11.
Multinational association for supportive care in cancer. Antiemetic Guidelines. 2005. Available at: http://www.mascc.org/. Accessed December 24, 2005.
12.
MartinM.The severity and pattern of emesis following different cytotoxic agents. Oncology.1996; 53(Suppl 1): 26–31.
13.
BeckT.M.The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs.1995; 6: 237–242.
14.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed Ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
15.
CarmichaelJ., KeizerH.J., CupissolD., MilliezJ., ScheidelP., SchindlerA.E.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9: 381–385.
16.
de WitR., de BoerA.C., vd LindenG.H., StoterG., SparreboomA., VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 19: 85: 1099–1101.
17.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119: 350–354.
18.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2: 177–183.
19.
GelingO., EichlerH.G.Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23: 1289–1294.
20.
StillwellT.J., BensonR.C.Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer.1988; 61: 451–457.
21.
RomoloJ.L., GoldbergN.H., HandeK.R., RosenbergS.A.Effect of hydratin on plasma-methotrexate levels. Cancer Treat Rep.1977; 61: 1393–1396.
22.
PitmanS.W., FreiE3rd. Weekly methotrexate-calcium leucovorin rescue: effect of alkalinization on nephrotoxicity: pharmacokinetics in the CNS; and use in CNS non-Hodgkin's lymphoma. Cancer Treat Rep.1977; 61: 695–701.
LymanG.H.Balancing the benefits and costs of colony-stimulating factors: a current perspective. Semin Oncol2003; 30(Suppl 13): 10–17.
26.
OzerH., ArmitageJ.O., BennettC.L.. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol.2000; 18: 3558–3585.
27.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49: 1796–1799.
28.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75: 397–402.
29.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35: 57–74.
30.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21: 33–64.
31.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: The Chemotherapy Sourcebook.3rd ed.PerryM.C., ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2001; 494–504.
32.
AronoffG.R., BernsJ.S., BrierMem (Eds). Drug Prescribing in Renal Failure.4th ed.Philadelphia, PA: American College of Physicians; 1999; 73.
33.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapy. Oncologist.2001; 6: 162–176.
